Showing results (91-100 of 192) with videos related to

Sort By:
Pageof 20
Clinical Genitourinary Cancer|January 15, 2018
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate CancerEdoardo Francini, Steven Yip, Shubidito Ahmed, et al.
Journal of Geriatric Oncology|July 26, 2018
Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trialSchroder Sattar, Shabbir M H Alibhai, Sarah Brennenstuhl, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPERAnthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 26, 2017
A randomized phase II trial of geriatric assessment and management for older cancer patientsMartine T E Puts, Schroder Sattar, Michael Kulik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancerHumberto Lara-Guerra, Thomas K Waddell, Maria A Salvarrey, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 11, 2016
Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods studyMartine T E Puts, Schroder Sattar, Kara McWatters, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumoursRobert H Jones, David J Pinato, Martin D Forster, et al.
Cancer Medicine|March 3, 2020
Cancer patients' experiences with immune checkpoint modulators: A qualitative studyKari Ala-Leppilampi, Natalie A Baker, Chris McKillop, et al.
European Urology Open Science|October 27, 2025
Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective TrialRui M Bernardino, Leyi B Yin, Katherine Lajkosz, et al.
British Journal of Cancer|June 26, 2023
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterationsSubotheni Thavaneswaran, Maya Kansara, Frank Lin, et al.
Pageof 20